Combination versus sequential single agent chemotherapy for metastatic breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combination versus sequential single agent chemotherapy for metastatic breast cancer

Published:2013-12-18 Issue:3 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Dear Rachel F¹,McGeechan Kevin²,Jenkins Marisa C³,Barratt Alexandra²,Tattersall Martin HN¹,Wilcken Nicholas¹⁴

Affiliation:

1. Sydney Medical School; The University of Sydney; Sydney Australia

2. Wiser Healthcare, Sydney School of Public Health, Faculty of Medicine and Health; The University of Sydney; Sydney Australia

3. Sydney School of Public Health; The University of Sydney; Sydney Australia

4. Medical Oncology; Crown Princess Mary Cancer Centre; Westmead Australia

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD008792.pub2/fullpdf

Reference38 articles.

1. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study;Alba;Journal of Clinical Oncology,2004

2. Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancer;Baker;Cancer,1974

3. Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC);Beslija;Journal of Clinical Oncology,2006

4. Combination versus sequential single agent chemotherapy in advanced breast cancer: association with metastatic sites and long-term survival;Chlebowski;British Journal of Cancer,1989

5. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma;Conte;Cancer,2004

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metastatic Prostate Cancer: Sequential or Combination Therapy?;Clinical Genitourinary Cancer;2024-12

2. Intraperitoneal administration of doxorubicin-encapsulated Brucea javanica oil nanoemulsion against malignant ascites;European Journal of Pharmaceutics and Biopharmaceutics;2024-09

3. A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer;International Journal of Molecular Sciences;2024-03-17

4. Towards Agility in Breast Cancer Treatment Principles as Adopted from Agile Software Engineering;Journal of Multidisciplinary Healthcare;2024-03

5. A novel alternative method for long‐term evaluation of male reproductive toxicity and its recovery using a pre‐pubertal mouse testis organ culture system;Journal of Applied Toxicology;2024-01-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3